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Aims Our objectives were to compare effectiveness and long-term prognosis after epicardial thoracoscopic atrial fibrilla-
tion (AF) ablation vs. endocardial catheter ablation, in patients with prior failed catheter ablation or high risk of
failure.
...................................................................................................................................................................................................
Methods
and results
Patients were randomized to thoracoscopic or catheter ablation, consisting of pulmonary vein isolation with op-
tional additional lines (2007–2010). Patients were reassessed in 2016/2017, and those without documented AF re-
currence underwent 7-day ambulatory electrocardiography. The primary rhythm outcome was recurrence of any
atrial arrhythmia lasting >30 s. The primary clinical endpoint was a composite of death, myocardial infarction, or ce-
rebrovascular event, analysed with adjusted Cox proportional hazard ratios (HRs). One hundred and 24 patients
were randomized with 34% persistent AF and mean age 56 years. Arrhythmia recurrence was common at mean
follow-up of 7.0 years, but substantially lower with thoracoscopic ablation: 34/61 (56%) compared with 55/63
(87%) with catheter ablation [adjusted HR 0.40, 95% confidence interval (CI) 0.25–0.64; P< 0.001]. Additional abla-
tion procedures were performed in 8 patients (13%) compared with 31 (49%), respectively (P< 0.001). Eleven
patients (19%) were on anti-arrhythmic drugs at end of follow-up with thoracoscopy vs. 24 (39%) with catheter ab-
lation (P= 0.012). There was no difference in the composite clinical outcome: 9 patients (15%) in the thoracoscopy
arm vs. 10 patients (16%) with catheter ablation (HR 1.11, 95% CI 0.40–3.10; P= 0.84). Pacemaker implantation
was required in 6 patients (10%) undergoing thoracoscopy and 3 (5%) in the catheter group (P= 0.27).
...................................................................................................................................................................................................
Conclusion Thoracoscopic AF ablation demonstrated more consistent maintenance of sinus rhythm than catheter ablation,
with similar long-term clinical event rates.
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Introduction
Atrial fibrillation (AF) is a common health problem with rising inci-
dence and prevalence, and high rates of stroke and mortality.1
Rhythm control with AF ablation is commonly used to treat symp-
tomatic and drug-resistant patients and to improve quality of life.2
Percutaneous catheter ablation is most often the first-line approach,
but long-term durability is modest.3 Other alternatives include surgi-
cal AF ablation using open heart surgery (Cox Maze), or a totally
thoracoscopic procedure, which retains high success rates but with a
minimally invasive approach.4
The FAST trial was the first randomized comparison of thoraco-
scopic and catheter ablation for AF in drug-refractory patients more
likely to fail catheter ablation, either with a history of previously failed
catheter ablation or factors suggesting an increased risk of failure of
endocardial ablation, including hypertension with left atrial dilatation.
One-year results confirmed a greater freedom from AF with thora-
coscopic ablation, but a higher peri-procedural rate of adverse events
than with catheter ablation.5 However, data on longer-term out-
comes directly comparing thoracoscopic and catheter ablation are
not currently available. Recent joint guidelines from the European
Society of Cardiology and the European Association of
Cardiothoracic Surgeons recommend that minimally invasive surgery
should be considered in patients with symptomatic AF when catheter
ablation has failed (IIaB). In symptomatic patients with persistent or
long-standing persistent AF that is drug refractory, catheter and surgi-
cal ablation have the same level of recommendation, but only based
on consensus opinion (IIaC).2
The present study extends the follow-up of patients randomized
in the FAST trial to examine long-term outcomes relating to the suc-
cess of rhythm control and major cardiovascular events. Our aim was
to determine the comparative efficacy of thoracoscopic vs. catheter
ablation in this patient group that is at higher risk of failure of catheter
ablation. Although we are not adequately powered for clinical end-
points, our analysis provides the only long-term data, and alongside
other ongoing clinical studies will provide additional information to
clinicians and patients about treatment options for symptomatic AF.
Methods
A prospective randomized clinical trial was designed to compare catheter
and thoracoscopic ablation in patients with drug-refractory AF referred
for further rhythm control. The study was performed at St. Antonius
Hospital in Nieuwegein, the Netherlands, and the Hospital Clı´nic in
Barcelona, Spain. The trial was registered (https://www.clinicaltrials.gov/
ct2/show/NCT00662701) and conducted in accordance with the
Helsinki Declaration. Enrolment started in July 2007 and was completed
in June 2010. Ethical approval for the original trial was obtained by both
hospitals and the Dutch Central Trial Registration Organization (VCMO/
CCMO). Ethical approval was again obtained for this extended follow-up
study by the Research Ethical Committees of both sites: Comite´ E´tico de
Investigacio´n Clı´nica del Hospital Clı´nic de Barcelona, Spain (HCB/2017/
0085) and Medical Research Ethics Committees United, Nieuwegein, the
Netherlands (NL55162.100.15).
Trial participants
Full details of the trial have previously been published.5 In brief, inclusion
criteria were symptomatic paroxysmal AF for more than 12 months, or
persistent AF confirmed by 7-day ambulatory electrocardiogram (ECG).
Patients were refractory to, or intolerant of, at least one anti-arrhythmic
drug, aged between 30 years and 70 years, and able to give informed con-
sent, with either failure of a prior catheter ablation, left atrial (LA) diame-
ter >_45 mm, or hypertension with LA 40–44 mm. Major exclusion
criteria were AF >1 year in duration, catheter or surgical procedures
within the last 3 months, previous stroke or transient ischaemic attack,
LA thrombus, LA diameter >65 mm, left ventricular ejection fraction
<45%, significant valve disease, and other major cardiovascular or non-
cardiovascular conditions.
Randomization and procedures
Block randomization was performed with concealed allocation using
sealed envelopes. Patients randomized to thoracoscopy underwent gen-
eral anaesthesia and pulmonary vein isolation (PVI) using radiofrequency
ablation under direct view through a video-assisted thoracoscopic ap-
proach as previously described,6 with optional additional ablation lines
and ganglionic plexus ablation. The LA appendage (LAA) was stapled and
excised in thoracoscopic patients under direct vision and echocardio-
graphic control. In the catheter ablation group, patients underwent PVI
with conscious sedation. Procedural details differed at each centre,5 but
all patients received radiofrequency ablation with optional lines at the dis-
cretion of the operator. All the patients with previous catheter ablation
were found to have at least one pulmonary vein with intact conduction
to left atrium before re-isolation. In both groups, patients were initially
treated with vitamin K antagonist oral anticoagulation for three months,
which was then continued at the discretion of the treating cardiologist
based on the CHADS2 and later CHA2DS2-VASc score. A blanking pe-
riod of 3 months was established in which pharmacological or electrical
cardioversion was allowed. After this period, all antiarrhythmic drugs
were suspended and any cardioversion after this period was considered a
procedural failure.
Patient follow-up
A 7-day ambulatory ECG was performed as part of the original study pro-
tocol at 6 and 12 months after randomization. Clinical follow-up was simi-
lar in both thoracoscopic and catheter-treated patients. Long-term
follow-up for this study in both centres consisted of a phone call or per-
sonal visit at the outpatient clinic in 2016, 12-lead ECG and documenta-
tion of current therapy (two patients in each arm were missing data on
medications). Patients with no history of AF recurrence at that time point
underwent a further 7-day ambulatory ECG. Major adverse clinical out-
comes were confirmed by medical records locally and through central
government records (Histo`ria Clı´nica Compartida, Departament de
Salut, Generalitat de Catalunya, Spain, and Municipal Personal Records
What’s new?
• The first long-term results after randomization of patients to
thoracoscopic vs. catheter ablation for atrial fibrillation (AF).
• Excellent and similar long-term freedom from death, myocar-
dial infarction, and cerebrovascular events with both thoraco-
scopic and catheter ablation.
• Accounting for older technologies used, there was still a high
rate of atrial arrhythmia recurrence in both arms.
• Thoracoscopic AF ablation was associated with more durable
maintenance of sinus rhythm over a 7-year period in this pa-
tient group who had initial, or high-risk of future failure from
catheter ablation.
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Database, The Netherlands). The European Society of Cardiology defini-
tions for myocardial infarction (MI), transient cerebral ischaemic attack,
and stroke were used to document cardiovascular events. Data were reg-
istered by independent researchers at both sites and Principal
Investigators had no access to data until the database was locked for
analysis.
Study outcomes
The primary rhythm endpoint was the first recurrence of any docu-
mented atrial arrhythmia lasting >30 s during follow-up. We also analysed
atrial arrhythmia recurrence in relevant subgroups (patients on and off
antiarrhythmic drugs at final follow-up, and according to prior catheter
ablation treatment, age, gender, and type of AF at baseline). Where long-
term follow-up was unavailable due to death, loss to follow-up or lack of
ambulatory ECG, the rhythm endpoint was censored to the last available
7-day ambulatory ECG to avoid bias (typically at 12 months).
The primary clinical endpoints were the composite cumulative fre-
quency of death, MI, or cerebrovascular event (transient ischaemic attack
or ischaemic/haemorrhagic stroke), and the time to the first of these
events. Secondary clinical endpoints were all-cause mortality and the
need for permanent pacemaker implantation. We also assessed for
bleeding requiring transfusion or surgery (not including peri-procedural
events).
Endpoints were defined prior to statistical analysis, based on knowl-
edge of available data and the prior publication of 1-year outcomes.5
Statistical analysis
Summary results are presented as percentages, or mean and standard de-
viation (SD). All analyses followed the principle of intention-to-treat.
Categorical outcomes were compared using the v2 test. Outcomes dur-
ing follow-up were analysed using a Cox proportional hazards regression
model, adjusted for baseline age, sex, AF type, and history of prior failed
catheter ablation. Analyses were stratified by enrolment site and cen-
sored at 2400 days. Hazard ratios (HRs) and 95% confidence intervals
(CIs) are presented, along with corresponding P-values. Kaplan–Meier
plots were used to graph results according to treatment arm, with
log-rank tests for comparison stratified by site. A post hoc analysis was
performed to account for the competing risk of death in relation to
arrhythmia recurrence using the method of Fine and Gray.7 There was
no evidence of violation of the proportional hazards assumption in any
multivariable model as determined by Schoenfeld residuals.
Aggregate data meta-analysis of the FAST trial data with two other
prospective randomized controlled trials8,9 was performed using the
method of Bagos and Nikolopoulos10 to account for differing follow-up
periods. In brief, incidence rates were calculated for each trial arm by mul-
tiplying the rate of arrhythmia recurrence with the person-months of
follow-up, and then incidence rate ratios calculated by comparing thora-
coscopic with catheter ablation. Values were then pooled using a fixed
effects model. Risk of bias was assessed using the Cochrane tool11 by two
investigators working independently and a third for adjudication.
A two-tailed P-value of 0.05 was considered statistically significant.
Analyses were performed on Stata Version 14.2 (StataCorp LP, TX,
USA).
Results
One hundred and 24 patients were included in the study, with 63
randomized and receiving catheter ablation and 61 to thoracoscopy
(Figure 1). Mean age was 56± 8 years at the time of inclusion, 81%
were male, and AF type was persistent in 34% (Table 1). The majority
of patients were included due to previous failed catheter ablation
(67%).
Median duration of hospitalization was 5.5 days for thoracoscopy
vs. 2.0 days for catheter ablation (P< 0.001). Procedural complica-
tions and peri-procedural adverse events have previously been de-
scribed and were higher with thoracoscopy.5 To summarize, in those
randomized to thoracoscopy, there were conversions to median
sternotomy for bleeding (n= 1), abandoned procedure with pro-
longed hospitalization (n= 1), haemothorax (n= 1), conservatively-
treated pneumothorax (n= 6), stroke (n= 1), pericardial tamponade
(n= 1), and rib fracture (n= 1). In the catheter ablation arm, one pa-
tient developed a pericardial effusion after transeptal puncture, one
patient had a transient ischaemic attack, and four patients developed
an uncomplicated (minor) groin haematoma.
n = 150 eligible
n = 21 refused
randomisation
n = 129 randomised
Thoracoscopic ablation
n = 63
n = 1 withdrawn consent
Catheter ablation
n = 66
Thoracoscopic ablation
n = 61
Catheter ablation
n = 63
Vital status in all patients*
n = 4 deaths
Vital status in all patients
n = 5 deaths
n = 2 further surgical
ablation (MAZE IV)
n = 20 repeat catheter
ablation for recurrent AF
n = 6 catheter ablation for
recurrent AF
n = 11 thoracoscopic
ablation for recurrent AF
RANDOMISATION
LONG-TERM FOLLOW-UP
n = 1 coronary artery
bypass graft plus maze
surgery
n = 1 withdrawn consent
n = 1 withdrawn due to
pulmonary vein anomaly
n = 1 withdrawn due to
right atrial flutter
Figure 1 Study flowchart. *For rhythm outcome in thoraco-
scopic arm, n = 3 censored at 1 year (n = 2 unwilling to have 7-day
ECG on follow-up due to lack of AF or symptoms and n = 1 moved
abroad). AF, atrial fibrillation; ECG, electrocardiogram.
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Long-term follow-up for vital status was successfully obtained in all
patients (Figure 1). The mean follow-up period was 7.0 years from
randomization (SD 1.5 years). At final follow-up, 11 patients (19%)
initially randomized to thoracoscopy were on anti-arrhythmic
drugs, vs. 24 (39%) allocated to catheter ablation (P= 0.012).
Corresponding numbers for oral anticoagulation were 19 patients
(32%) in the thoracoscopy arm, vs. 32 patients (52%) with catheter
ablation (P= 0.024).
Rhythm outcomes
Across all recruited participants, recurrence of atrial arrhythmias was
common, occurring in 89/124 patients (72%). Patients randomized to
thoracoscopic ablation had lower recurrence rates during extended
follow-up; 34/61 (56%) compared with 55/63 (87%) with catheter ab-
lation. The adjusted HR was 0.40, 95% CI 0.25–0.64; P< 0.001
(Table 2). Kaplan–Meier curves are presented in Figure 2A, showing
high early failure in both groups. This was followed by a high rate of
arrhythmia recurrence in the catheter ablation arm up to 3 years of
follow-up, much greater than in those randomized to thoracoscopy.
All arrhythmia recurrences were AF in the catheter ablation group.
With thoracoscopy, recurrence was AF in 32 patients (94%) and left
atrial flutter in 2 patients (6%).
Additional ablation procedures (catheter or surgical) were per-
formed in 8 patients (13%) randomized to thoracoscopy and 31 (49%)
for to catheter ablation (P< 0.001) (Figure 1). In patients free of anti-
arrhythmic drug use on final follow-up, the difference between thora-
coscopy and catheter ablation for arrhythmia recurrence was consis-
tent with the overall results (adjusted HR 0.49, 95% CI 0.27–0.89;
P= 0.019). Atrial arrhythmia recurrence was lower in thoracoscopy
patients compared with catheter ablation for all patient subgroups, in-
cluding those with an without prior catheter ablation, and by age, sex
and type of AF (Figure 3; all interaction P-values non-significant).
Meta-analysis combining our long-term study with 12-month data
from two other prospective randomized trials confirmed a lower
rate of incident atrial arrhythmia recurrence after thoracoscopic vs.
catheter ablation. The pooled incidence rate ratio was 0.55, 95% CI
0.38–0.78, with P-value of 0.001, no heterogeneity between trials
(I2 = 0%; P= 0.43), but variable risk of bias (Figure 4).
Clinical outcomes
Beyond the initial procedural complications, there were no differen-
ces in adverse clinical events between groups. The composite of
death, MI, or cerebrovascular event (transient ischaemic attack,
ischaemic or haemorrhagic stroke) occurred in 9/61 patients (15%)
assigned to thoracoscopy and 10/63 (16%) to catheter ablation. The
adjusted HR for time to first event was 1.11, 95% CI 0.40–3.10;
P= 0.84 (Figure 2B).
Although we were not powered to detect a different in all-cause
mortality, this was similar in both groups (adjusted HR 0.94, 95% CI
0.18–4.94; P= 0.95). Four patients (7%) died in the thoracoscopic
arm, with one due to cardiovascular causes. Five patients (8%) died in
the catheter group, with four due to cardiovascular causes. Major
bleeding requiring transfusion or surgery (not including peri-
procedural events) occurred in 0 patients (0%) receiving thoraco-
scopic ablation and 1 patient (2%) with catheter ablation. Pacemaker
implantation was required in 6 patients (10%) in the thoracoscopy
arm and 3 (5%) randomized to catheter ablation (P= 0.27). A list of
all outcomes by treatment arm is presented in Table 3.
.................................................................................................
Table 1 Baseline characteristics
Characteristics Thoracoscopic
ablation
(N561)
Catheter
ablation
(N5 63)
Male 45 (74%) 55 (87%)
Age (years), mean ± SD 56.1 ± 8.0 56.0 ± 7.2
Body mass index (kg/m2),
mean ± SD
27.8 ± 4.6 28.6 ± 3.5
Prior myocardial infarction 0 2 (3.2%)
Left ventricular ejection fraction (%),
mean ± SD
57.7 ± 6.8% 55.5 ± 8.2%
LA diameter (mm), mean ± SD 42.5 ± 6.5 43.2 ± 4.8
Reason for randomization
Prior failed catheter ablation 45 (74%) 38 (60%)
LA diameter 40–45 mm and
hypertension
8 (13%) 15 (24%)
LA diameter >_45 mm 8 (13%) 10 (16%)
AF type
Paroxysmal AF 45 (74%) 37 (59%)
Persistent AF 16 (26%) 26 (41%)
AF, atrial fibrillation; LA, left atrial; SD, standard deviation.
....................................................................................................................................................................................................................
Table 2 Multivariate analysis
Outcomes Thoracoscopic
ablation, events (n)
Catheter ablation,
events (n)
Thoracoscopic vs. catheter
ablation; hazard ratio (95% CI)a
P-value
Atrial arrhythmia recurrence 34/61 (56%) 55/63 (87%) 0.40 (0.25–0.64) <0.001
Atrial arrhythmia recurrence accounting
for the competing risk of death
– – 0.43 (0.27–0.70) 0.001
Death, myocardial infarction or cerebro-
vascular event
9/61 (15%) 10/63 (16%) 1.11 (0.40–3.10) 0.84
All-cause mortality 4/61 (7%) 5/63 (8%) 0.94 (0.18–4.94) 0.95
aAdjusted for baseline age, sex, AF type and history of prior failed catheter ablation, stratified by recruitment site.
4 M. Castella´ et al.
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38
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17
36
12
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9
Thoracoscopic ablation Catheter ablation
27
9
16
4
61
63
59
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58
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33
25
1 2 3
Time (years)
4 5
Log rank P < 0.001 Log rank P = 0.83
6 7 0 1 2 3
Time (years)
4 5 6 7
A B
Figure 2 Kaplan–Meier curves for the primary rhythm and clinical endpoints. (A) Time to atrial arrhythmia recurrence after the blanking period.
(B) Time to first event—death, MI, or cerebrovascular event (transient ischaemic attack, ischaemic, or haemorrhagic stroke). MI, myocardial
infarction.
Thoracoscopic versus catheter ablation: Atrial arrhythmia recurrence
Interaction
P-value
Use of AAD:
No AAD at follow-up (51/85) 0.93
0.77
0.66
0.70
0.28
0.1 0.5
Adjusted hazard ratio for atrial arrhythmia recurrence
Less recurrence with
thoracoscopic ablation
1.0 2.0
AAD at follow-up (32/35)
Catheter ablation:
No previous (29/40)
Previous ablation (55/84)
Age at randomisation:
Age <57 years (37/58)
Age ≥57 years (47/66)
Sex:
Type of AF:
Paroxsymal AF (52/86)
Persistent AF (32/38)
Women (14/22)
Men (70/102)
All patients (89/124)
Figure 3 Thoracoscopic vs. catheter ablation: arrhythmia recurrence by subgroup. Numbers in brackets are the number of patients with recur-
rence/total number in that subgroup. AAD, antiarrhythmic drugs; AF, atrial fibrillation.
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Discussion
The FAST trial is the only randomized evaluation of thoracoscopic vs.
catheter ablation for AF with long-term follow-up (mean of 7 years).
Thoracoscopic ablation after prior catheter ablation failure or in
patients with dilated left atrium and hypertension was associated
with higher rates of sinus rhythm maintenance, and significantly less
patients required additional ablation or antiarrhythmic medication
compared with those in the catheter ablation group. Whereas thora-
coscopic ablation was associated with higher rates of peri-procedural
adverse events, there were no differences in the long-term clinical
composite endpoint of mortality, MI, or cerebrovascular events com-
pared to catheter ablation. Our results provide reassurance for the
safety of both procedures in symptomatic patients refractory or in-
tolerant to anti-arrhythmic drugs.
Recurrence of atrial arrhythmias was common in this trial. We
have to emphasize the high standard for failure in this trial, a single
30 s episode of atrial tachyarrhythmia in 7 years searched with 7-day
ambulatory ECG. Typically, ‘success’ of AF ablation strategies (includ-
ing in the FAST trial) has been the maintenance of sinus rhythm, de-
spite the knowledge of only modest rates of sinus rhythm in long-term
studies.3 Our trial confirms that arrhythmia recurrence is frequent
in the long-term after ablation, even if AF burden and symptoms may
improve. The risk of AF recurrence, despite multiple ablation proce-
dures, has important implications on stroke prevention, in particular
the continuation of anticoagulation even after apparently successful
ablation, as reflected in the ESC/EACTS 2016 Guidelines for AF man-
agement.2 The similar rate of thromboembolic events in our study in
the two groups, despite LAA exclusion in the thoracoscopic arm and
lower rates of arrhythmia recurrence, should remind us that not all
thromboembolic events arise from the LAA, and that AF is an inflam-
matory and pro-thrombotic condition.
Contemporary rates for maintenance of sinus rhythm after abla-
tion are higher than we document due to recent advances, including
new technologies such as better mapping or catheters. In the FIRE
and ICE trial of paroxysmal AF patients, freedom from atrial arrhyth-
mia or need for further treatment was 65% at 12 months.12 In the
STAR-AF trial of persistent AF patients, there was 49% freedom
from AF recurrence at 18 months.13 Second generation cryoballoon
Meta-analysis of prospective randomised trials
Atrial arrhythmia recurrence
Number
randomised
124 84
(mean)
68.9% 0.64 (0.42-0.98) L L L L
L
L L
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Figure 4 Meta-analysis of incident rate ratios for arrhythmia recurrence in prospective randomized trials. Summary data for the three randomized
controlled trials of thoracoscopic vs. catheter ablation for AF. Note that each study had different inclusion criteria, ablation strategies, and use of anti-
arrhythmic drug therapy during follow-up. The incidence rate ratio is the rate of arrhythmia recurrence weighted by person-months of follow-up
comparing thoracoscopic with catheter ablation. Cochrane risk of bias domains are (from left to right): sequence generation, allocation concealment,
blinding, incomplete outcome data, selective reporting and other threats to validity; scored as low risk (L), unclear risk (U), or high risk (H) of bias.
AF, atrial fibrillation; CI, confidence interval; I2, heterogeneity.
.................................................................................................
Table 3 Endpoints for thoracoscopic and catheter
ablation
Outcomes Thoracoscopic
ablation
(N561)
Catheter
ablation
(N5 63)
All-cause mortality 4 (7%) 5 (8%)
Cardiovascular death 1 (2%) 4 (6%)
Non-cardiovascular death 2 (3%) 0 (0%)
Unknown cause of death 1 (2%) 1 (2%)
Myocardial infarction 1 (2%) 0 (0%)
Cerebrovascular eventa,b 5 (8%) 6 (10%)
Stroke 4 (7%) 2 (3%)
Transient ischaemic attack 2 (3%) 4 (6%)
Intracranial haemorrhage 0 (0%) 1 (2%)
Bleeding requiring transfusion
or surgery
0 (0%) 1 (2%)
Permanent pacemaker implantation 6 (10%) 3 (5%)
Outcomes are from the day of the procedure to last follow-up.
aOne patient in each group had both a transient ischaemic attack and stroke.
bOne patient in each group had a fatal cerebrovascular event and so are also in-
cluded in the cardiovascular death outcome.
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have shown 64% freedom from AF at 12 months in persistent AF
patients.14 Our catheter ablation results using monopolar radiofre-
quency catheters are broadly similar to other published data in the
same period.15 Surgical techniques have also improved during our
follow-up period, including bipolar clamps able to perform wider ab-
lation lines, and standardized conductance-based protocols that al-
low for more applications and better transmurality than during the
FAST trial. Hence, success rates from ablation are likely higher now
for both catheter and thoracoscopic ablation.
Our findings were consistent in meta-analysis pooling the two
other prospective randomized controlled trials.8,9 Albeit with shorter
12-month follow-up than our data, the absence of heterogeneity in
treatment effect comparing thoracoscopy and catheter ablation with
different procedures and patient populations is reassuring. Although
our sample size limits full assessment, we found no evidence of any
difference in patient subgroups, with all patients having lower ar-
rhythmia recurrence with thoracoscopic compared to catheter abla-
tion. This included patients with persistent forms of AF, where the
interaction P-value was non-significant but we clearly lacked power.
The optimal strategy of ablation in these patients remains to be iden-
tified. Studies have demonstrated the superiority of the full Cox
Maze lesion set as the most effective pattern in maintaining sinus
rhythm in persistent AF when lesions are performed surgically with
bipolar radiofrequency or cryothermy.16 However, recent studies in
the surgical and catheter field suggest that additional lines, when added
to PVI, do not necessarily improve results in patients with persistent
AF.13 New approaches to AF management, including enhanced clinical
phenotyping and identification of atrial function and atrial damage
(fibrosis, dilatation, complex or aberrant focal ECGs) may result in
better classification and stratification of therapy in the future.17
Availability of thoracoscopic ablation remains limited globally and
due to the invasive approach, it is unlikely this could be recom-
mended for initial treatment of AF in most patients at present.
Instead, guidelines have suggested that thoracoscopic ablation is a
useful treatment option in those patients refractory to other ther-
apy.2 The FAST trial included patients at higher risk of catheter abla-
tion failure, which in addition to the epicardial ablation and LAA
excision afforded by the thoracoscopic approach, may have led to
better rhythm outcomes. Like other interventional procedures, there
is evidence of a learning curve with thoracoscopic ablation, and also
that complications can be reduced in expert hands to a similar level
as seen with percutaneous approaches.18 If this trend continues,
along with better technologies and patient selection, there may be a
wider role for thoracoscopic procedures in the future.19 Although
recently presented data did not identify a clinical advantage from
catheter ablation over drug therapy,20 further study data are awaited
to establish if early control of rhythm can lead to improved prognosis
for patients with AF. Our findings show better rhythm outcomes for
thoracoscopic ablation, but future studies also need to demonstrate
whether these approaches can robustly improve quality of life.
Limitations
Not all patients enrolled in the FAST trial had prior catheter ablation,
reflecting clinical practice whereby it may not be ethical to proceed
with an endocardial intervention in patients at increased risk of treat-
ment failure. Those that underwent prior ablation were often treated
in other referring centres, and so information on the number of
previous procedures was not always available. This study describes
the longest follow-up of patients randomized to thoracoscopic vs.
catheter ablation. However, the original study protocol was one
year, and subsequent follow-up was not performed in a regular,
protocol-driven manner, but rather at a fixed time point. For this rea-
son, we were unable to calculate time periods on and off antiarrhyth-
mic drugs. We used a strict definition of recurrence of any single
episode of atrial arrhythmia >30 s in duration, consistent with con-
sensus documents,21 although does not differentiate between AF and
other rhythms such as atrial macro re-entrant tachycardia. Further,
we performed 7-day ambulatory ECG in all patients without prior
clinical recurrence of AF. However, we were not able to assess AF
burden, and some atrial arrhythmia episodes may not necessarily re-
flect AF, which may have contributed to the low overall rates for
maintenance of sinus rhythm. We do not present data on the type of
arrhythmia recurrence, which in clinical practice could differ depend-
ing on endocardial or epicardial approaches. By chance, there was a
lower number of persistent AF patients in the thoracoscopic ablation
group, and despite no evidence of interaction in treatment effect, fur-
ther randomized data in this population is clearly warranted. The
meta-analysis is limited by the small number of randomized trials in
this field, the variable risk of bias, and the relatively short duration of
the other trials that required an incidence rate assessment for atrial
arrhythmia recurrence. As already noted, the technologies used are
now outdated have now been superseded both for thoracoscopic
and catheter ablation. Finally, the sample size is clearly insufficient to
power for clinical outcomes even over this long time period, although
we demonstrate reassuringly low rates of death, MI and cerebrovas-
cular events after both thoracoscopic and catheter ablation.
Conclusion
For symptomatic AF patients with previous failed catheter ablation
or structural changes, thoracoscopic ablation is associated with lower
rates of recurrence of atrial arrhythmias compared to catheter abla-
tion. Thoracoscopic PVI and LAA excision was associated with higher
rates of peri-procedural events and a longer initial hospital stay. Both
thoracoscopic and catheter ablation patients had low rates of major
adverse clinical outcomes during 7-year follow-up.
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